1062. Daptomycin/ceftaroline in combination versus vancomycin for the treatment of methicillin resistant Staphylococcus aureus bacteremia
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
  • CEFT_DAPTO_IDWEEK 2018.pdf (439.5 kB)
  • Background:

    Vancomycin has historically been the mainstay of therapy for MRSA bacteremia, but severe infections due to vancomycin-intermediate Staphylococcus aureus have emerged. In vitro studies have shown that the combination of a β-lactam antibiotic, such as ceftaroline with daptomycin, was synergistic against MRSA. The purpose of this study was to compare outcomes in patients who received daptomycin and ceftaroline in combination versus vancomycin for the treatment of MRSA bacteremia.


    This was a retrospective exploratory cohort study approved by the institutional review board at Cooper University Hospital. Patients were included if they received daptomycin/ceftaroline (cases) or vancomycin (controls) for the treatment of MRSA bacteremia between November 2010 and March 2017. Cases were matched 1:1 with controls based on source of MRSA bacteremia, age within 10 years, and renal function. The primary endpoint was clinical cure, defined as the improvement of signs and symptoms of bacteremia. Secondary endpoints included microbiologic cure, time to sterilization of blood cultures, duration of hospital stay, overall mortality, and MRSA related mortality.


    Forty-one cases were included. There was no statistical difference between the two groups in microbiologic cure, time to sterilization of blood cultures, overall mortality or MRSA related mortality. There were no significant differences between patients in each group including in those with ICU admissions and who required vasopressors. Cases were significantly more likely to have hardware compared to the control group (43.9% versus 12.2%; p = 0.0014). Clinical cure was achieved in 27 patients (65.9%) in the case group and 26 patients (63.4%) in the control group (p = 0.8173). Patients in the case group had a statistically longer mean hospital duration (29 days versus 21 days respectively, p= 0.0206) and more secondary complications such as bone infection (p = 0.0076).


    Time to sterilization of blood cultures and overall mortality were similar in both groups. Patients in the combination group had longer hospital stays compared to vancomycin monotherapy. Daptomycin/ceftaroline combination therapy is an option for complicated MRSA bacteremia. Larger studies should be conducted to further evaluate this combination.

    Matthew Fox, PharmD Candidate1, Klarida Zeqollari, PharmD Candidate2, Grant Lee, PharmD Candidate2, Laura Pontiggia, PhD1, Dana Byrne, MD, MSCE3, Jessica Adams, PharmD, BCPS, AAHIVP1, Madeline King, Pharm D4 and Lucia Rose, PharmD3, (1)University of the Sciences, Philadelphia, PA, (2)University of the Sciences, philadelphia, PA, (3)Cooper University Hospital, Camden, NJ, (4)Pharmacy, University of the Sciences, Philadelphia College of Pharmacy, Philadelphia, PA


    M. Fox, None

    K. Zeqollari, None

    G. Lee, None

    L. Pontiggia, None

    D. Byrne, None

    J. Adams, None

    M. King, None

    L. Rose, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.